このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Portable Absence Seizure Detection Using Smart Earbuds (PAUSE)

2026年11月12日 更新者:Universitaire Ziekenhuizen KU Leuven

Typical absence seizures are the hallmark of idiopathic generalized epilepsy syndromes (CAE, JAE, JME) but are frequently underreported in patient diaries. Clinical studies have shown that 74% to 94% of absence seizures go unreported by patients or caregivers. While 24-hour video-EEG (vEEG) is the gold standard for quantification, it is expensive, hospital-based, and lacks the temporal resolution required for long-term management.

Previous studies successfully validated a wearable EEG (wEEG) solution using a behind-the-ear (BTE) form factor (Byteflies Sensor Dot). In the pilot study, the authors demonstrated that a reduced electrode configuration combined with ML algorithms could detect absence seizures with 98% sensitivity in the hospital setting and enable effective home-based treatment monitoring.

To expand the applicability of this method, validation of additional form factors is required. This study aims to extend our validation framework to a novel wEEG device that utilizes an ear configuration (earEEG).

調査の概要

詳細な説明

  1. Background, rationale and risk assessment

    1.1 Disease Background Typical absence seizures are the clinical hallmark of idiopathic generalized epilepsy syndromes, specifically Childhood Absence Epilepsy (CAE), Juvenile Absence Epilepsy (JAE), and Juvenile Myoclonic Epilepsy (JME)(1). These syndromes account for up to 20% of all people living with epilepsy, primarily affecting children, adolescents, and young adults(2). Clinically, absences are characterized by a transient loss of consciousness accompanied by generalized 3 Hz (2.5-5.5 Hz) spike-and-wave discharges (SWD) on the electroencephalogram (EEG). These seizures can have significant cognitive, affective, and behavioral comorbidities, particularly when not adequately controlled(1,3-5).

    1.2 Limitations of the Current Standard of Care Accurate quantification of the seizure burden is essential for optimizing the treatment with anti-seizure medications (ASM). The current standard of care relies on seizure diaries. However, previous studies indicate that the sensitivity of self-reporting for absence seizures ranges from 6% to 26% compared with video-EEG(6,7). i.e., seizure diaries have low reliability.

    Therefore, patients are intermittently followed with a 24-hour video electroencephalogram (vEEG), which has, among other limitations, high costs (approximately €1,200 per session in Belgium), long waiting times, and limited ecological validity, as they provide only a snapshot of the patient's condition that may not capture cyclical seizure variability(8).

    This study seeks to validate an objective, automated counting method using a wearable EEG (wEEG) device, first in a hospital setting and then at home.

    1.3 Rationale for Wearable EEG wEEG devices offer a promising alternative to full-scalp vEEG for long-term monitoring. By using a limited number of electrodes combined with Machine Learning (ML) algorithms, wEEG can enable intermittent or continuous, objective seizure counting outside the hospital.

    Researchers from ESAT-STADIUS & UZ Leuven have previously validated this approach using a behind-the-ear (BTE) wEEG device (The Sensor Dot, Byteflies, Antwerpen, Belgium). In a pilot study, an ML algorithm developed by the group achieved 98% sensitivity for detecting absence seizures in a hospital setting compared to standard EEG(6). Furthermore, a subsequent home-based pilot demonstrated the feasibility of using this system for treatment optimization(9).

    1.4 Justification for the Current Investigation While the BTE form factor has been validated, it may not be the optimal solution for all patients due to cosmetic concerns, comfort, or lifestyle constraints. To facilitate widespread adoption and personalized care, it is necessary to validate alternative wEEG form factors, such as earEEG.

    The device under investigation in this study, the NeuroBuds™, uses a novel ear electrode configuration that lacks rigorous clinical validation against the gold standard for absence seizure detection.

    Therefore, the primary purpose of this study is to validate the signal quality and diagnostic accuracy of the ESAT-STADIUS ML algorithms on the signals recorded with the Neurobuds against simultaneous standard vEEG. This validation is a prerequisite for developing a device-agnostic ML algorithm capable of processing data from various manufacturers and electrode montages.

    1.5 Benefit/Risk Assessment The IMD is CE-marked, non-invasive, and poses minimal risk to participants, comparable to that of standard scalp EEG electrodes. The potential risks are limited to mild skin irritation or discomfort at the electrode sites. The potential benefit is the validation of a less invasive monitoring alternative. Successful validation may allow for future home-based seizure quantification.

  2. Investigation objectives & design

2.1 Investigation objectives

Primary Objective The primary objective of this investigation is to validate the diagnostic accuracy of an investigational ear wEEG device, namely the NeuroBuds (Cebreo Medical), and an ML algorithm in detecting typical absence seizures. Specifically, the study aims to determine the sensitivity, precision, F1-score, and the FAR/24h of the ML seizure detection algorithm applied to signals recorded by the IMD, compared with simultaneous gold-standard video-EEG (vEEG) annotated by a neurologist.

Secondary Objectives

  1. Signal Quality: To assess the signal quality and artifact susceptibility of novel electrode form factors (earEEG) compared to standard wet scalp electrodes.
  2. Usability and Comfort: To evaluate patient and caregiver acceptance, comfort, and ease of use of the IMD in both hospital and home environments.
  3. Home Validation: To demonstrate the robustness of the data collection pipeline and algorithm performance in a real-world home environment, distinct from the controlled hospital setting.

Hypothesis In the hospital setting, the ML algorithm will achieve seizure-detection sensitivity of ≥90% (relative to simultaneous neurologist-annotated vEEG) after analyzing the data obtained with the IMD. These results should be comparable to those previously achieved with the BTE wEEG.

2.2 Primary endpoint

The primary endpoint is the diagnostic performance of the automated absence seizure detection algorithm using the investigational device data, measured by:

  • Sensitivity (Recall): The proportion of true absence seizures (defined as 3Hz Spike and Wave Discharges ≥ 3 seconds identified on the gold-standard vEEG) that are correctly detected by the wEEG algorithm.
  • Precision: the proportion of positive predictions that were actually correct when compared to the vEEG.
  • F1-score: a harmonic mean metric used to evaluate the overall performance of the ML model. It uses both precision and sensitivity.
  • False Alarm Rate (FAR): The number of false positive detections per 24 hours of recording.

2.3 Secondary endpoints

Signal Quality Metrics: Comparative hourly analysis of root mean square (RMS) and signal-to-noise ratio in the alpha band (SNR-Alpha) in the signals originated with the IMD channels and the spatially corresponding channels of the standard 10-20 EEG.

Usability Scores: Quantitative assessment of user experience (patients/caregivers) using standardized questionnaires (i.e., System Usability Scale, final questionnaire-comfort & user experience, and User Perspective Questionnaire).

Data Yield: The percentage of interpretable (artifact-free) data obtained during unsupervised home recording sessions.

References

  1. Hirsch E, French J, Scheffer IE, et al. ILAE definition of the Idiopathic Generalized Epilepsy Syndromes: Position statement by the ILAE Task Force on Nosology and Definitions. Epilepsia. 2022;63(6):1475-1499. doi:10.1111/epi.17236
  2. Jallon P, Latour P. Epidemiology of Idiopathic Generalized Epilepsies. Epilepsia. 2005;46(s9):10-14. doi:10.1111/j.1528-1167.2005.00309.x
  3. Caplan R, Siddarth P, Stahl L, et al. Childhood absence epilepsy: Behavioral, cognitive, and linguistic comorbidities. Epilepsia. 2008;49(11):1838-1846. doi:10.1111/j.1528-1167.2008.01680.x
  4. Gruenbaum BF, Sandhu MRS, Bertasi RAO, et al. Absence seizures and their relationship to depression and anxiety: Evidence for bidirectionality. Epilepsia. 2021;62(5):1041-1056. doi:10.1111/epi.16862
  5. Callenbach PMC, Bouma PAD, Geerts AT, et al. Long-term outcome of childhood absence epilepsy: Dutch Study of Epilepsy in Childhood. Epilepsy Res. 2009;83(2-3):249-256. doi:10.1016/j.eplepsyres.2008.11.011
  6. Swinnen L, Chatzichristos C, Jansen K, et al. Accurate detection of typical absence seizures in adults and children using a two-channel electroencephalographic wearable behind the ears. Epilepsia. 2021;62(11):2741-2752. doi:10.1111/epi.17061
  7. Pizarro J, O'Sullivan S, Walker MC. How accurately do adult patients report their absence seizures? Epilepsia Open. Published online March 28, 2023:epi4.12689. doi:10.1002/epi4.12689
  8. Baud MO, Kleen JK, Mirro EA, et al. Multi-day rhythms modulate seizure risk in epilepsy. Nat Commun. 2018;9(1):88. doi:10.1038/s41467-017-02577-y
  9. Macea J, Chatzichristos C, Bhagubai M, De Vos M, Van Paesschen W. Tailoring antiseizure treatment with a wearable device: A proof-of-concept study in absence epilepsy. Epilepsia. 2025;66(7):2295-2306. doi:10.1111/epi.18384

研究の種類

観察的

入学 (推定)

25

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

6年歳以上 (子、大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

サンプリング方法

非確率サンプル

調査対象母集団

Adults and children with idiopathic generalized epilepsy syndromes and typical absence seizures.

説明

Inclusion Criteria:

  1. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures.
  2. At least 18 years of age at the time of signing the ICF or at least 6 years of age at the time their parents/legal representatives sign the caregiver's IFC and the minor participants sign the age-appropriate IFC.
  3. Confirmed diagnosis of the following idiopathic generalized epilepsy syndromes: CAE, JAE, or JME.
  4. Use of highly effective methods of birth control; defined as those that, alone or in combination, result in low failure rate (i.e., less than 1% per year) when used consistently and correctly; such as implants, injectables, combined oral contraceptives, some Intra-Uterine Devices (IUDs), true sexual abstinence (i.e. refraining from heterosexual intercourse during the entire period of risk associated with the investigation treatment(s)) or commitment to a vasectomised partner.
  5. Language: Subject and/or legal guardian must be able to understand the study instructions and the Informed Consent documents. These will be available in English and Dutch.

Exclusion Criteria:

  1. Patient has a history of other generalized epilepsy syndromes, such as Lennox-Gastaut.
  2. Anatomical Constraints: Anatomical abnormalities of the outer ear or ear canal that prevent the proper fit of the earEEG device.
  3. Participation in another clinical trial with an investigational drug or device that would interfere with the endpoints of this study.
  4. Female who is pregnant, breastfeeding, or intends to become pregnant or is of child-bearing potential and not using an adequate, highly effective contraceptive

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 観測モデル:CASE_ONLY
  • 時間の展望:PROSPECTIVE

コホートと介入

グループ/コホート
Absence patients

Adults and children with idiopathic generalized epilepsy syndromes, i.e., Childhood Absence Epilepsy, Juvenile Absence Epilepsy, and Juvenile Myoclonic Epilepsy, with active disease and having typical absences.

Prospective, single-center, open-label, comparative diagnostic accuracy study. Study participants will be contacted during the screening phase based on the scheduled admission for 24-hour vEEG in the epilepsy monitoring units of UZ Leuven. After screening and signing the IFC, they will be asked to come to the hospital for ear-mold imprinting. These prints will serve as the basis for customizing the headset. The study will employ a hybrid design, consisting of two phases:

Phase A (In-Hospital Validation: participants will wear the IMD simultaneously with the standard 10-20 scalp EEG montage. This provides the ground truth labels for validation.

Phase B (At home): participants will wear the device at least once a week for 3 weeks to assess real-world usability

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Sensitivity (Recall)
時間枠:1 day, during simultaneous use of the IMD and 25-channel scalp EEG (in-hospital phase)

The proportion of true absence seizures (defined as 3Hz Spike and Wave Discharges ≥ 3 seconds identified on the gold-standard vEEG) that are correctly detected by the wEEG algorithm.

1 day, during simultaneous use of the IMD and 25-channel scalp EEG (in-hospital phase)
Precision
時間枠:1 day, during simultaneous use of the IMD and 25-channel scalp EEG (in-hospital phase)

The proportion of positive predictions that were actually correct when compared to the vEEG.

1 day, during simultaneous use of the IMD and 25-channel scalp EEG (in-hospital phase)
F1-score
時間枠:1 day, during simultaneous use of the IMD and 25-channel scalp EEG (in-hospital phase)

The harmonic mean metric used to evaluate the overall performance of the ML model. It uses both precision and sensitivity.

1 day, during simultaneous use of the IMD and 25-channel scalp EEG (in-hospital phase)
False Alarm Rate in 24 hours
時間枠:1 day, during simultaneous use of the IMD and 25-channel scalp EEG (in-hospital phase)

The number of false positive detections per 24 hours of recording.

1 day, during simultaneous use of the IMD and 25-channel scalp EEG (in-hospital phase)

二次結果の測定

結果測定
メジャーの説明
時間枠
Signal quality
時間枠:1 day, during simultaneous use of the IMD and 25-channel scalp EEG (in-hospital phase)

Comparative hourly analysis of root mean square (RMS) and signal-to-noise ratio in the alpha band (SNR-Alpha) in the signals originated with the IMD channels and the spatially corresponding channels of the standard 10-20 EEG.

1 day, during simultaneous use of the IMD and 25-channel scalp EEG (in-hospital phase)
Usability Scores
時間枠:3 weeks, when the IMD will be used during 24 hours continuously at least once a week.

Quantitative assessment of user experience (patients/caregivers) using standardized questionnaires (i.e., System Usability Scale, final questionnaire-comfort & user experience, and User Perspective Questionnaire).

3 weeks, when the IMD will be used during 24 hours continuously at least once a week.
Data Yield
時間枠:3 weeks, when the IMD will be used during 24 hours continuously at least once a week.

The percentage of interpretable (artifact-free) data obtained during unsupervised home recording sessions.

3 weeks, when the IMD will be used during 24 hours continuously at least once a week.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

協力者

捜査官

  • 主任研究者:Lauranne Scheldeman、UZ Leuven

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2027年1月11日

一次修了 (推定)

2027年12月31日

研究の完了 (推定)

2027年12月31日

試験登録日

最初に提出

2026年9月30日

QC基準を満たした最初の提出物

2026年11月12日

最初の投稿 (実際)

2026年11月18日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月18日

QC基準を満たした最後の更新が送信されました

2026年11月12日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

Two years after the analysis, we will post the database, along with all measurements and code, on OpenNeuro.

IPD 共有時間枠

Two years after the analysis, we will post the database, along with all measurements and code, on OpenNeuro.

IPD 共有アクセス基準

It will be open access

IPD 共有サポート情報タイプ

  • ANALYTIC_CODE

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する